daily in divided doses) and fludrocortisone (100 jg daily) was started and she was discharged a few days later having improved clinically and with normal serum electrolytes.
She was readmitted two weeks later with oedema, dyspnoea and a 3 kg weight gain. She was tachypnoeic and basal crepitations were heard in the chest; blood pressure was 120/70 mmHg and she was afebrile. Chest X-ray showed cardiomegaly and pulmonary congestion. On echocardiography the heart valves and chamber sizes were normal but there was a small pericardial effusion. The electrocardiogram was normal. There was no suggestion of non-compliance with the treatment regimen or dispensing error. She was treated with intravenous frusemide and the fludrocortisone dose was reduced to 50 jg daily and then stopped after two days. Over the next four days her cardiac failure improved and diuretic therapy was withdrawn. She was discharged a week after admission. Two months later her serum and urine electrolytes and cortisol day profile were normal. Aldosterone was undetectable in either supine or recumbent posture but fludrocortisone was not restarted. Eight months later, she was admitted with acute addisonian crisis (serum sodium 118mmol/L, potassium 6.2mmol/L) following acute gastritis and responded well to intravenous fluid and hydrocortisone. Fludrocortisone was started with a dose of 25 4ug daily and increased to 100 jg over two months. On review after four months she was doing well, without fluid retention, and her serum electrolytes were normal. COMMENT The association of congestive cardiac failure with fludrocortisone therapy was reported by Knowlton and Baer in 7 of 22 adults with Addison's disease followed for over 30 yearsl. All had unrelated ischaemic, valvular, or hypertensive heart disease and were elderly. The dose of hydrocortisone and fludrocortisone did not differ between the groups with and without heart failure. Derish et al. reported an 11-year-old boy with Addison's disease who developed cardiac failure due to a reversible cardiomyo-pathy2; and Willis et al. described heart failure secondary to fludrocortisone and hydrocortisone therapy in a 6-year-old boy with Addison's disease3.
The patient reported here was started on a standard dose of fludrocortisone. There was no suggestion of abnormal myocardial function before the onset of congestive failure. When myocardial function is normal, an increase in circulatory volume is expected to increase contractility but further increases in the volume load will eventually cause it to decline. We attribute the fluid overload and heart failure in our patient to fludrocortisone therapy. The possible explanation could be renal adaptation to chronic salt and water deprivation. With mineralocorticoid replacement, this previously adaptive mechanism may have resulted in sodium and water retention, leading to heart failure. This view is supported by the fact that, over the subsequent months, the patient tolerated a gradually increasing dose of fludrocortisone. Osseous metaplasia in colorectal adenocarcinoma is a histological curiosity. Until now, the condition has been described only in left colonic lesions. Here we report a patient in whom osseous metaplasia developed in a caecal adenocarcinoma. wall. The adenocarcinoma was moderately differentiated with extensive local spread to subcutaneous fat, anterior abdominal wall muscle and periumbilical tissue. Bony trabeculation was seen in the part of tumour which extended into the anterior abdominal wall (Figure 1 ). The liver metastases had no bone formation. COMMENT In contrast to dystrophic calcification, which frequently occurs in necrotic areas of cancer, bone formation is extremely rare. Review of the published work from 1970 onwards revealed only 8 other cases of osseous metaplasia in colorectal adenocarcinoma ( Table 1 ). The male to female ratio is 2:1 (6/3) and the mean age of patients 62.1 years (47-83). 5 of 9 had arisen in rectal tumours, 2 in sigmoid, 1 in transverse colon and 1 (this case) in the caecum. Osseous metaplasia is found at the primary site in twothirds of cases and in a metastatic site in one-third.
Osseous metaplasia in caecal adenocarcinoma
Do tumour cells themselves undergo osseous metaplasia or secrete substances that induce the condition in stromal fibroblasts? We favour the latter hypothesis for the following reasons. The osteoblasts in metaplastic regions are often surrounded by stromal fibroblastsl-7. Electron microscopy does not show any cell types intermediate between tumour cells and osteoblasts6, but both the osteoblasts and the adjacent stromal cells stain for alkaline phosphatase5. Bone formation in connective tissue stroma (intramembranous ossification) is well recognized in the embryo.
The histopathologist should be aware of osseous metaplasia in colorectal cancer to avoid misdiagnosis of carcinosarcoma, which carries a worse prognosis8. The Table 1 Published cases (after 1970) of osseous metaplasia in colorectal adenocarcinoma
